Stifel, Edwards Lifesciences
Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests that recent conversations with six Transcatheter aortic valve replacement (TAVR) physicians and a follow-up survey of thirty doctors support the view that TAVR growth could re-accelerate in 2025.
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...
Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...
Today, Benzinga's options scanner spotted 8 options trades for Edwards Lifesciences. This is not a typical pattern. The ...
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback